High Grade Prostate Cancer Articles & Analysis
9 news found
These molecules can bind to targets highly expressed on cancer cell surfaces and be targeted during drug delivery. For example, folic acid (folates) can be used. Cancer and embryonic cells preferentially use the folate receptor (FR), which has a high affinity for folic acid (K_d = 1–10nM) and can uptake folic acid via receptor-mediated ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate ...
In the first presentation, entitled “IsoPSA: Clinical Performance of a Single Parameter, Structure Based Test for High Grade Prostate Cancer in a Large, Multicenter, Prospective Validation Trial”, Dr. Klein provided data used to validate the diagnostic accuracy of the novel, structure-based IsoPSA assay to improve ...
The EPI-CE test demonstrated comparable results to the US ExoDx Prostate test with high sensitivity of 92% and high negative predictive value (NPV) of 89% for ruling out clinically significant prostate cancer. ...
James McKiernan, Professor of Urology at Columbia University, demonstrated that using the ExoDx Prostate test, or EPI, resulted in good performance ruling out high-grade (Gleason 7 or higher) prostate cancer (HGPCa) in prior negative biopsy patients with the previously validated 15.6 cut-point. ...
” Cleveland Diagnostics was recently awarded Breakthrough Device Designation by FDA, which allows Cleveland Diagnostics to work more closely and frequently with FDA to expedite the review of its prostate cancer assay, IsoPSA®. Two recent multicenter clinical trials, in which the diagnostic accuracy of IsoPSA was compared to that of traditional ...
Published studies from multicenter prospective clinical trials suggest that the non-invasive, blood-based IsoPSA assay has significant superior diagnostic accuracy when compared to traditional prostate-specific antigen (PSA) tests in detecting high-grade prostate cancer. ...
The study validated the findings from a preliminary study published earlier in European Urology, demonstrating that the non-invasive, blood-based IsoPSA assay has superior diagnostic accuracy over the current gold standard, prostate-specific antigen (PSA), in detecting high-grade prostate cancer. ...
The findings illustrate a significantly improved diagnostic accuracy over the current gold standard, prostate-specific antigen (PSA), for both detection of any prostate cancer as well as high-grade prostate cancer. ...